Catalyst Calendar

Thu, May 28, 2026

1 updates

10:13 AM

ProMIS Neurosciences to Participate in Upcoming Conferences in June

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one...

promisneurosciences.com

Tue, May 12, 2026

1 updates

PMN

6:30 AM

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD)....

Interim Data • Phase 1Interim analysis Wed, Jul 1, 2026promisneurosciences.com

Mon, Apr 27, 2026

1 updates

PMN

10:30 AM

Targeting underlying causes of neurodegenerative diseases | 2026 Bloom Burton & Co. Healthcare Investor Conference

2026 Bloom Burton & Co. Healthcare Investor Conference "Targeting underlying causes of neurodegenerative diseases" Presented by Neil K. Warma CEO, ProMIS Neurosciences Presented on 4/21/2026

promisneurosciences.com